This valuable study provides insights into a key question in comparative neuroanatomy and development. The authors provide evidence of the role for a particular micro-RNA in regulating the development ...

DB-1305/BNT325 was generally well tolerated and exhibited “very encouraging and durable antitumor activity in ovarian cancer patients,” said Maria Rubinstein, MD.

Researchers are exploring the effectiveness of combining antibody drug conjugates and immune checkpoint inhibitors in non-small cell lung cancer. Precision medicine has improved the prognosis for ...

Researchers from Heidelberg Pharma AG have presented a new antibody-drug conjugate (ADC) that shows promise for treating pancreatic ductal adenocarcinoma (PDAC). The ADC, called hRS7 ATAC, targets ...

The poster is available on Innate Pharma’s website. IPH4502 is a differentiated topoisomerase I inhibitor Antibody Drug Conjugate (ADC) conjugated to exatecan targeting Nectin-4, a cell adhesion ...

its novel and differentiated topoisomerase I inhibitor Antibody Drug Conjugate (ADC) targeting Nectin-4. The data were presented at the American Association for Cancer Research (AACR) Annual ...

Roche has claimed a breakthrough designation from the FDA for a cancer test that combines an antibody assay with ...

Antibody-drug conjugates have emerged as one of the most popular treatment modalities for investment in recent years. Following Pfizer’s proposed move for Seagen, Ben Hargreaves tracked how the ...

The second ADC, SGN-CD19A (Seattle Genetics), comprises a humanized anti-CD19 monoclonal antibody conjugated with MMAF using the noncleavable MC, which is the same linker–cytotoxic agent ...